MENU
+Compare
RDY
Stock ticker: NYSE
AS OF
Feb 21 closing price
Price
$13.35
Change
-$0.09 (-0.67%)
Capitalization
12.48B

RDY stock forecast, quote, news & analysis

RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for RDY with price predictions
Feb 21, 2025

RDY sees MACD Histogram crosses below signal line

RDY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RDY as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

RDY moved below its 50-day moving average on January 23, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RDY crossed bearishly below the 50-day moving average on January 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for RDY moved below the 200-day moving average on January 22, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RDY entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RDY's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

RDY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RDY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.833) is normal, around the industry mean (59.993). P/E Ratio (19.682) is within average values for comparable stocks, (90.174). Projected Growth (PEG Ratio) (4.879) is also within normal values, averaging (2.987). Dividend Yield (0.007) settles around the average of (0.122) among similar stocks. P/S Ratio (3.786) is also within normal values, averaging (19.928).

A.I.Advisor
published Dividends

RDY paid dividends on August 12, 2024

Dr. Reddy's Laboratories Ltd RDY Stock Dividends
А dividend of $4.78 per share was paid with a record date of August 12, 2024, and an ex-dividend date of July 30, 2024. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.61B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 77%, and the average quarterly price growth was 50%. ECGS experienced the highest price growth at 99%, while DHBUF experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 165%. For the same stocks of the Industry, the average monthly volume growth was 322% and the average quarterly volume growth was 662%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 64
SMR Rating: 83
Profit Risk Rating: 90
Seasonality Score: -43 (-100 ... +100)
View a ticker or compare two or three
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
8-2-337, Road No. 3
Phone
+91 4049002900
Employees
25863
Web
https://www.drreddys.com